1. Home
  2. REPL vs INN Comparison

REPL vs INN Comparison

Compare REPL & INN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REPL
  • INN
  • Stock Information
  • Founded
  • REPL 2015
  • INN 2010
  • Country
  • REPL United States
  • INN United States
  • Employees
  • REPL N/A
  • INN N/A
  • Industry
  • REPL Biotechnology: Pharmaceutical Preparations
  • INN Real Estate Investment Trusts
  • Sector
  • REPL Health Care
  • INN Real Estate
  • Exchange
  • REPL Nasdaq
  • INN Nasdaq
  • Market Cap
  • REPL 780.3M
  • INN 708.0M
  • IPO Year
  • REPL 2018
  • INN 2011
  • Fundamental
  • Price
  • REPL $11.85
  • INN $6.75
  • Analyst Decision
  • REPL Strong Buy
  • INN
  • Analyst Count
  • REPL 6
  • INN 0
  • Target Price
  • REPL $17.50
  • INN N/A
  • AVG Volume (30 Days)
  • REPL 818.5K
  • INN 747.7K
  • Earning Date
  • REPL 02-06-2025
  • INN 02-24-2025
  • Dividend Yield
  • REPL N/A
  • INN 4.75%
  • EPS Growth
  • REPL N/A
  • INN N/A
  • EPS
  • REPL N/A
  • INN 0.07
  • Revenue
  • REPL N/A
  • INN $736,287,000.00
  • Revenue This Year
  • REPL N/A
  • INN $0.15
  • Revenue Next Year
  • REPL $300.41
  • INN $1.08
  • P/E Ratio
  • REPL N/A
  • INN $92.17
  • Revenue Growth
  • REPL N/A
  • INN 0.72
  • 52 Week Low
  • REPL $4.92
  • INN $5.66
  • 52 Week High
  • REPL $17.00
  • INN $7.22
  • Technical
  • Relative Strength Index (RSI)
  • REPL 51.79
  • INN 52.31
  • Support Level
  • REPL $10.05
  • INN $6.67
  • Resistance Level
  • REPL $11.20
  • INN $6.89
  • Average True Range (ATR)
  • REPL 0.92
  • INN 0.14
  • MACD
  • REPL -0.08
  • INN -0.01
  • Stochastic Oscillator
  • REPL 51.97
  • INN 69.17

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

About INN Summit Hotel Properties Inc.

Summit Hotel Properties Inc is a U.S.-based hotel investment company focusing on select-service hotels in the upscale and upper-midscale properties in the U.S. Substantially all of Summit's assets are held and operated by its Operating Partnership, Summit Hotel OP, LP, in which the company holds general and limited partnership interests. The firm has one segment in activities related to investing in real estate. Summit's revenue streams include Room and Other hotel operations revenue. Room comprises the majority of total revenues. The firm's hotels are located in various markets, such as corporate offices, retail centers, airports, state capitols, convention centers, and leisure attractions. Summit's hotels operate under brands, including Marriott, Hilton, Hyatt, and Holiday Inn.

Share on Social Networks: